Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Shahzad Mustafa
A High Proportion of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (Wks) of Treatment
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Response to PCV13 Vaccination in Patients With Multiple Myeloma Versus Healthy Controls
Human Vaccines and Immunotherapeutics
Medicine
Allergy
Immunology
Pharmacology
Related publications
Clinically Meaningful Improvements in Asthma Control Questionnaire (ACQ) Scores Occur Early, While Asthma-Related Quality of Life (AQLQ) Scores Continue to Improve Over 52 Weeks, Among Patients With Eosinophilic Asthma Receiving IV Reslizumab
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma
Pulmonologiya
Pulmonary
Respiratory Medicine
Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma
Prescriber
Pharmacology
Evaluation of Eosinophilic Asthma Patients Without Blood Eosinophil (EOS) Response to Intravenous (IV) Reslizumab in a Post-Hoc Analysis of 52-Week Placebo-Controlled Phase 3 Studies
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Variability in Absolute Blood Eosinophil (EOS) Counts Over 52 Weeks in Patients With Inadequately Controlled Eosinophilic Asthma Receiving Placebo in Two Duplicate Clinical Trials
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma
Annals of Allergy, Asthma and Immunology
Respiratory Medicine
Pulmonary
Allergy
Immunology
Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
Allergy: European Journal of Allergy and Clinical Immunology
Allergy
Immunology
Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration
Journal of Allergy and Clinical Immunology
Allergy
Immunology
